Starling Oncology Q3 10-Q: Revenue Up 24.3%, $11.6M Debt-Extinguishment Loss, Going-Concern Language
STLN has more than doubled off its 52-week low of $2.32.
Summary
Starling's Q3 10-Q confirms 24.3% revenue growth to $169.8 million and positive Adjusted EBITDA, but shows an $11.6 million loss on the July convertible-note refinancing, a new $25 million revolver, and going-concern evaluation language against a $299.4 million accumulated deficit.
Key Events · Earnings and Guidance · STLN
-
Q3 Revenue Grows 24.3%
Total operating revenue was $169,767 thousand versus $136,564 thousand a year earlier, led by specialty pharmacy revenue of $109,304 thousand, up 44.0%.
-
$11.6M Loss on Debt Extinguishment
Repaying the ~$86 million 4.00% Senior Secured Convertible Notes on July 1, 2026 with a $75 million OrbiMed term loan plus 10,025,535 warrants at $8.567 produced an $11,561 thousand non-operating loss.
-
New $25M Asset-Based Revolver
The Gemino/SLR Healthcare ABL signed August 20, 2026 had $5,000 drawn and $5,016 available at September 30, 2026, priced at Term SOFR plus 3.95%.
-
Going-Concern Evaluation Disclosed
The filing cites a $299,448 thousand accumulated deficit and $28,029 thousand nine-month net loss, though management concluded liquidity is sufficient for at least one year.
Analysis · STLN · Industrial Applications And Services
The Q3 numbers were already out on November 5, but the full 10-Q carries the balance-sheet story. Revenue rose 24.3% to $169.8 million, yet the company swung to a $2,982 thousand operating loss from an $8,054 thousand loss a year earlier; Adjusted EBITDA turned positive at $3,394 thousand versus negative $3,459 thousand. The catch sits below the operating line: an $11.6 million loss on extinguishing the old Deerfield convertible notes, funded by a new $75 million OrbiMed term loan plus 10,025,535 warrants struck at $8.567, and a fresh $25 million asset-based revolver with $5,000 drawn. Management states it has sufficient liquidity for at least one year, but the filing still carries going-concern evaluation language against a $299,448 thousand accumulated deficit. Moreover, the term loan's minimum net revenue covenant of $700 million starts with the twelve months ending December 31, 2027 — a bar the company does not currently clear on an annualized basis. Four insiders, including the CEO and CFO, also adopted 10b5-1 selling plans during the quarter.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, STLN was trading at $5.84 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $669.9M. The 52-week trading range was $2.32 to $7.13. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.